---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-291705"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:40:18.042267+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon expands Akoya companion diagnostic deal to $17.3M for ACR-368 OncoSignature test

## Summary
- Third Amendment with Akoya increases total milestone payments to $17.3M through FDA pre-market approval for multiple indications.
- $3.8M in milestones already achieved and paid to date; cash runway unchanged from Nov 2023 10-Q.
- Expanded scope of work covers development of ACR-368 companion diagnostic test across multiple indications.

## SEC filing metadata
- accession: 0001193125-23-291705
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/0001193125-23-291705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/d608194d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-291705
- JSON: https://secwatch.observer/filing/0001193125-23-291705.json
- Plain text: https://secwatch.observer/filing/0001193125-23-291705.txt

## Key facts
- Material Agreements
  Acrivon Therapeutics, Inc. amended OncoSignature Diagnostic Agreement with Akoya Biosciences, Inc. valued at $17,300,000 (effective 2023-12-04).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Akoya Biosciences, Inc.
  - Value: $17,300,000
  - Effective: 2023-12-04
  source text: On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/0001193125-23-291705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.